XML 33 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Reporting
 3 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
Segment Reporting

The Company’s chief operating decision maker (the “CODM”), who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance.

 

Aytu manages our Company and aggregates our operational and financial information in accordance with two reportable segments: Aytu BioScience and Aytu Consumer Health. The Aytu BioScience segment consists of the Company’s prescription products. The Aytu Consumer Health segment contains the Company’s consumers healthcare products line, which was the result of the Innovus Merger. Select financial information for these segments is as follows:

 

   Three months Ended September 30,
   2020  2019
 Consolidated revenue:          
 Aytu BioScience  $5,752,000   $1,440,000 
 Aytu Consumer Health   7,768,000    —   
 Consolidated revenue   13,520,000    1,440,000 
           
 Consolidated net loss:          
 Aytu BioScience   (2,950,000)   (4,929,000)
 Aytu Consumer Health   (1,356,000)   —   
 Consolidated net loss   (4,306,000)   (4,929,000)

 

   As of  As of
   September 30,  June 30,
   2020  2020
 Total assets:          
 Aytu BioScience  $116,499,000   $126,267,000 
 Aytu Consumer Health   24,772,000    26,569,000 
 Total assets  $141,271,000   $152,836,000